We evaluated an immunochemiluminometric assay for total triiodothyronine (T3)inserum. Acridiniumesterisused as chemiluminescent label, with magnetic particie separation. Intra-run precision was demonstrated by CVs of 8.6%, 8.1%, and 4.4% at T3 concentrations of 1.3, 2.2, and 4.3 nmol/L, respectively. Between-run CV5 were 19.1%, 8.8%, and 6.9% at respective T3 concentrations of 0.9, 2.4, and 6.2 nmoi/L. We tested the validity of a two-point calibration system by comparing it with a set of 10 calibrators; use of the latter only minimally improved assay precision. The central 95% reference range, determined by data from 109 healthy blood donors, was 1.5-3.2 nmol/L. Comparison with a standard radioimmunoassay method revealed constant error, attributed to bias or matrix effects between the different calibrators used in the two assay systems. Assay time for60 samples was 2.5 h. We conclude that this assay is rapid and precise, and offers safety and time advantages over conventional RIA techniques. During the 1970s, chemiluminescent immunoassays were developed with isoluminol as a luminescent label (2). In 1983, a chemiluminescent assay involving acrmdinium ester as a luminescent label was described (3).Photon emission, the result of oxidation of acridiium ester in the presence of base and peroxide, occurs within 2 s in the conditions of this assay, allowing rapid quantification of the signal by a photomultiplier tube (4). Immunoassays based on acridinium esters can theoretically provide greater sensitivity than RIAs (4).
MA. 'l."riLevel" Ligand Controls, levels A, B, and C, were purchased from Ciba-Corning Diagnostics, Irvine, CA. 3,3',5-Triiodothyronine was purchased from Sigma Chemical Co., St.
Louis, MO.
Interference studies with bilirubin and free hemoglobin were performed by addition to human serum pools in a ratio of 100 L of interferent or saline to 900 L of serum. We used a stock bilirubin solution of 1700 nmol/L and a lysed erythrocyte preparation with hemoglobin at 30 g/L.
Equipment
A photomultiplier tube detector is required to quantify results. We used a "Magic LiteAnalyzer H," which injects the two reagents sequentially into each tube containing sample, then measures photon emission.Raw data are given by the analyzer as relative light units (RLUs). The analyzer is calibrated for each lot of reagents by entering a manufacturer-generated 10-point "Master Curve" into its software. Each run includes two calibrators, the RLUs of which are algorithmically used to recalibrate the Master Curve for that run.
Procedures
Magic Lite Assay. The assay protocol recommended by the manufacturer was followed throughout.
Sample T3 (50 tzL) is dissociated from its binding proteins by the addition of 100 pL of anilmnonaphthalenesulfonic acid (ANS) in an alkaline solution. T3 bound to paramagnetic particles (500 ILL) competes with T3 in the sample for binding with murine monoclonal anti-T3 antibody labeled with acridinium ester (100 .tL). The kinetics of this reaction are identical to those of a standard RIA. After separation in a magnetic separator unit, unbound antibody is washed away and the amount of bound antibody is quantifIed luminometrically.
All calibrators, controls, and samples were run in duplicate. The total assay time for 60 tubes is approximately 2.5 h.
Radioimmunoassay.
We compared the results of the Magic Lite assay with those of our in-house radioimmunoassay. Sample T3 is dissociated from its binding proteins by the addition of ANS in alkaline buffer at a pH of 8. The sample is incubated with anti-T3 antibody (American Bioclinical, Portland, OR) for 20 min, then ['251]T3 (Amersham, Arlington Heights, IL) is added for a 1-h incubation at 37#{176}C and a subsequent 2-h incubation at 4#{176}C. Antibodybound T3 is separated from free T3 by precipitation with polyethylene glycol, followed by centrifugation.
The radioactivity in the bound fraction is counted in a gamma counter. Each run is calibrated by using a set of five standards, obtained from Baxter.
The reference range (mean ± 2 SD) is 1-3 nmol/L. We obtained between-run CVs of 19.5%, 7.3%, and 7.5% at T3 concentrations of 0.6, 2.5, and 4.1 nmol/L, respectively.
The lowest concentration of these quality-control materials is the same as we used in the Corning Magic Lite assay. The lower limit of detection is 0.8 nmol/L. Results by this RIA are linearly related toT3 concentration to 4.6 nmolJL. Precision. Within-run precision was assessed by replicate analysis of each of five human serum pools; between-run precision was assessed with quality-control materials in consecutive runs (Table 1) .
Linearity.
Four patients' samples, with T3 concentrations of 3-5 nmol/L, were serially diluted with a 50 g/L solution of albumin in phosphate-buffered saline; analysis demonstrated a linear response down to 0.6 nmoIJL. Three patients' samples, supplemented with T3 to give concentrations of 12-23 nmol/L, were serially diluted with isotonic saline (NaCl 150 mmolJL); analysis demonstrated a linear response from concentrations s12 nmol/L down to 0.6 nmol/L. Analytical recovery. Data for analytical recovery studies are shown in Table 2 .
Interferences.
Four opaque lipemic samples gave identical results before and after ultracentrifugation.
There was also no interference (n = 4) from bilirubin at final concentrations <170 molIL, or from free hemoglobin at final concentrations <1 g/L (faint hemolysis). However, free hemoglobin at concentrations of 1.5 g/L (significant hemolysis) produced a mean increase in T3 values of 32% (n = 4, SD = 9%). When we added to serum samples (n = 5) a solution of thyroxin (1287 nmol/L) in a 9:1 (by vol) ratio, all samples showed cross-reactivity of <0.5%. Lower limit of detection. Twenty replicates of zero calibrator were analyzed in one run and the mean and standard deviation of the RLUs were calculated. Calculating the mean minus 3 SD of the zero signal resulted in a lower limit of detection, 0.6 nmolJL. The calculated detection limit was 0.4 nmol/L when we used mean minus 2 SD. The CV of RLUs for the 20 replicates was 4%.
Two vs 10 calibrators compared. The aim of these experiments was to investigate the validity of the two-calibrator system provided with the kit; the concentrations of these two calibrators were 1.32 and 5.54 nmol/L. We performed 15 assays in which both two-and 10-calibrator sets were assayed and used to calculate sample results in parallel; the values of the 10 calibrators were used to create a complete calibration curve for each assay. These assays included both patients' samples and quality-control samples. Minimal difference in between-assay precision with use of 10 calibrators vs two calibrators was demonstrated with aliquots of quality-control material (Table 3 ). Comparison of patients' samples calculated with two-point calibration vs 10-point calibration (Figure 1) showed no sta- Reference range. We analyzed sera from 109 healthy volunteer blood bank donors, 39% female and 61% male, ages 18-75 years. The range of their T3 concentrations was 1.4-3.3 nmoUL (mean 2.34 nmoIJL). Exclusion of the highest and lowest 2.5 percentiles gave a central 95% reference range of 1.5-3.2 nmol/L; however, the reference range was identical when calculated as mean ± 2 SD. There was no statistical difference (P <0.05) between T3 values for those 60 (mean T3 = 2.2 nmoIJL, SD = 0.51, n = 16) and those <60 years old (mean T3 = 2.3 nmolJL, SD = 0.43, n = 93).
The immunochemiluininescent assay overcomes many of the major disadvantages of radioimmunoassays and is equivalent to our in-house RIA in analytical performance.
No radioactive materials are used, the reagents involved are safe, and the shelf-life of the reagents is long (at least six months). However, use of this assay requires a luminometer, which may not be available in all laboratories.
The lower limit of detection of the assay (0.4 nmol/L) is not a substantive improvement over our RIA method (0.8 nmolJL), and does not match that stated by the manufacturer (0.2 nmol/L). However, given the lack of diagnostic specificity of a low T3, this is of little consequence.
The reference range determined by our analysis (1.5-3.2 nmol(L) was identical to that suggested by the manufacturer.
Comparison of assay results with those obtained by inhouse RIA revealed minimal proportional error. Results of the recovery studies also argue against proportional error. The substantial constant error between the two methods is attributable either to matrix effects or bias between the differing calibrators used in these assays. Evidence for bias is the measured T3 content of the Baxter zero calibrator when analyzed in the Magic Lite assay; however, matrix effects cannot be ruled out. Because we did not measure the Ciba-Corning calibrators with our in-house assay, we cannot prove the presence of bias. Further evidence for differences between commercially available calibrators can be seen in the variations of T3 results seen in surveys of the American College of Physicians (CAP) (5).Further study of this issue is indicated.
Between-run CV for thisassay was 8.8% at a T3 concentration of 2.3 nmolJL, which compared favorably with our RIA performance of CV of 7.3% for T3 at 2.5 nmol/L. This level of performance compares favorably with that of other commercially available RIA kits (6) .
Both the Magic Lite and RIA methods have diminished precision at T3 values <1.5 mnol/L. This loss of precision for low concentration of T3 is not serious, however, because low-T3 results are insensitive and nonspecific for clinical diagnosis (7).
Values for RLUs can vary significantly from day to day, a function of ambient temperature (4). RLUs cannot be directly compared with those obtained on another day, but only related to the RLUs of the calibrators on the same run.
There is negligible difference between the two-and 10-calibrator systems as measured by between-run CVs of quality-control materialsand by comparison ofresultsfor patients' samples. The use of the two-calibrator system provided by the manufacturer is therefore validated, saving costs and time.
Fraser (8) has suggested that the analytical goal for identi1ring disease by serial testing is CV(analytical) 1/2 CV(individual).
For T3, CV (individual) = 10.4% (9); therefore, the goal for CV(analytical) is 5.2%, which is not achieved by this assay or by our RIA. As seen above, other commercially available kits also do not meet this goal (6) .
We conclude that, based on its precision, safety, rapidity, and simplicity, this immunochemiluminometric assay, "T3 Magic Lite," may be considered a satisfactory replacement for radioimmunoassay in a clinical laboratory.
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